Open Label Extension Study of Conatumumab and AMG 479


NCT01327612

Interventional

Phase 2

Completed
The purpose of this protocol is to allow continued treatment with conatumumab and/or AMG 479, with or without chemotherapy to subjects without disease progression whose previous studies were closed.
Mar 03,2011
All
18 Years
N/A
12

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.